Clinical Trial Update: CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR [NA]

View source ↗

Summary

Clinical trial update for NK cell therapy in AML patients not in complete remission; the study is terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor NK Cell Based Therapy

Snippet

Sponsor: Miltenyi Biotec B.V. & Co. KG | Conditions: Acute Myelogenous Leukemia | NA | Status: TERMINATED | Results posted: 2019-05-07